203 related articles for article (PubMed ID: 17145606)
1. Pharmacokinetics of hydroxyurea 1,000 mg coated breakable tablets and 500 mg capsules in pediatric and adult patients with sickle cell disease.
de Montalembert M; Bachir D; Hulin A; Gimeno L; Mogenet A; Bresson JL; Macquin-Mavier I; Roudot-Thoraval F; Astier A; Galactéros F
Haematologica; 2006 Dec; 91(12):1685-8. PubMed ID: 17145606
[TBL] [Abstract][Full Text] [Related]
2. The influence of renal function on hydroxyurea pharmacokinetics in adults with sickle cell disease.
Yan JH; Ataga K; Kaul S; Olson JS; Grasela DM; Gothelf S; Kutlar A; Orringer E
J Clin Pharmacol; 2005 Apr; 45(4):434-45. PubMed ID: 15778424
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemia.
Estepp JH; Melloni C; Thornburg CD; Wiczling P; Rogers Z; Rothman JA; Green NS; Liem R; Brandow AM; Crary SE; Howard TH; Morris MH; Lewandowski A; Garg U; Jusko WJ; Neville KA;
J Clin Pharmacol; 2016 Mar; 56(3):298-306. PubMed ID: 26201504
[TBL] [Abstract][Full Text] [Related]
4. Hydroxyurea therapy lowers circulating DNA levels in sickle cell anemia.
Ulug P; Vasavda N; Kumar R; Keir L; Awogbade M; Cunningham J; Rees DC; Menzel S; Thein SL
Am J Hematol; 2008 Sep; 83(9):714-6. PubMed ID: 18615556
[TBL] [Abstract][Full Text] [Related]
5. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
Italia K; Jain D; Gattani S; Jijina F; Nadkarni A; Sawant P; Nair S; Mohanty D; Ghosh K; Colah R
Blood Cells Mol Dis; 2009; 42(1):25-31. PubMed ID: 18954999
[TBL] [Abstract][Full Text] [Related]
6. The effect of hydroxyurea on the coagulation system in sickle cell anemia and beta-thalassemia intermedia patients: a preliminary study.
Koc A; Gumruk F; Gurgey A
Pediatr Hematol Oncol; 2003 Sep; 20(6):429-34. PubMed ID: 14631615
[TBL] [Abstract][Full Text] [Related]
7. The measurement of urinary hydroxyurea in sickle cell anaemia.
Dalton RN; Turner C; Dick M; Height SE; Awogbade M; Inusa B; Okpala I; O'Driscoll S; Thein SL; Rees DC
Br J Haematol; 2005 Jul; 130(1):138-44. PubMed ID: 15982356
[TBL] [Abstract][Full Text] [Related]
8. Decreased plasma endothelin-1 levels in children with sickle cell disease treated with hydroxyurea.
Lapouméroulie C; Benkerrou M; Odièvre MH; Ducrocq R; Brun M; Elion J
Haematologica; 2005 Mar; 90(3):401-3. PubMed ID: 15749673
[TBL] [Abstract][Full Text] [Related]
9. Malignancy in patients with sickle cell disease.
Schultz WH; Ware RE
Am J Hematol; 2003 Dec; 74(4):249-53. PubMed ID: 14635205
[TBL] [Abstract][Full Text] [Related]
10. Hydroxyurea therapy lowers TCD velocities in children with sickle cell disease.
Kratovil T; Bulas D; Driscoll MC; Speller-Brown B; McCarter R; Minniti CP
Pediatr Blood Cancer; 2006 Dec; 47(7):894-900. PubMed ID: 16526051
[TBL] [Abstract][Full Text] [Related]
11. Experimental therapy of sickle cell disease. Use of hydroxyurea.
Charache S
Am J Pediatr Hematol Oncol; 1994 Feb; 16(1):62-6. PubMed ID: 7508689
[TBL] [Abstract][Full Text] [Related]
12. Circulating endothelin-3 levels in patients with sickle cell disease during hydroxyurea treatment.
Makis AC; Hatzimichael EC; Kolios G; Bourantas KL
Haematologica; 2004 Mar; 89(3):360-1. PubMed ID: 15020278
[TBL] [Abstract][Full Text] [Related]
13. Long-term hydroxyurea treatment in children with sickle cell disease: tolerance and clinical outcomes.
de Montalembert M; Brousse V; Elie C; Bernaudin F; Shi J; Landais P;
Haematologica; 2006 Jan; 91(1):125-8. PubMed ID: 16434381
[TBL] [Abstract][Full Text] [Related]
14. Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study.
Wang WC; Helms RW; Lynn HS; Redding-Lallinger R; Gee BE; Ohene-Frempong K; Smith-Whitley K; Waclawiw MA; Vichinsky EP; Styles LA; Ware RE; Kinney TR
J Pediatr; 2002 Feb; 140(2):225-9. PubMed ID: 11865275
[TBL] [Abstract][Full Text] [Related]
15. Hydroxyurea therapy: improving the lives of patients with sickle cell disease.
Anderson N
Pediatr Nurs; 2006; 32(6):541-3. PubMed ID: 17256291
[TBL] [Abstract][Full Text] [Related]
16. DNA damage in blood leukocytes of individuals with sickle cell disease treated with hydroxyurea.
Friedrisch JR; Prá D; Maluf SW; Bittar CM; Mergener M; Pollo T; Kayser M; da Silva MA; Henriques JA; da Rocha Silla LM
Mutat Res; 2008 Jan; 649(1-2):213-20. PubMed ID: 17988936
[TBL] [Abstract][Full Text] [Related]
17. Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males.
Berthaut I; Guignedoux G; Kirsch-Noir F; de Larouziere V; Ravel C; Bachir D; Galactéros F; Ancel PY; Kunstmann JM; Levy L; Jouannet P; Girot R; Mandelbaum J
Haematologica; 2008 Jul; 93(7):988-93. PubMed ID: 18508803
[TBL] [Abstract][Full Text] [Related]
18. [Hydroxyurea treatment in patients affected with sickle cell anemia: efficacy and safety].
de Montalembert M
Transfus Clin Biol; 2008; 15(1-2):34-8. PubMed ID: 18499496
[TBL] [Abstract][Full Text] [Related]
19. [The use of hydroxyurea in severe forms of sickle cell disease: study of 47 Tunisian paediatric cases].
Mellouli F; Bejaoui M
Arch Pediatr; 2008 Jan; 15(1):24-8. PubMed ID: 18164913
[TBL] [Abstract][Full Text] [Related]
20. Hydroxyurea for children with sickle cell disease.
Heeney MM; Ware RE
Pediatr Clin North Am; 2008 Apr; 55(2):483-501, x. PubMed ID: 18381097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
